ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.6 EUR | -.--% |
|
+1.03% | -.--% |
| 30/05 | Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs | MT |
| 30/05 | Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs | RE |
| Sales 2024 * | 4.3TCr 3.96TCr 3,58500Cr | Sales 2025 * | 5.26TCr 4.85TCr 4,38900Cr | Capitalization | 74TCr 68TCr 61,61100Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 1.19TCr 1.1TCr 1LCr | Net income 2025 * | 1.66TCr 1.53TCr 1,38100Cr | EV / Sales 2024 * | 17.6 x |
| Net Debt 2024 * | 1.81TCr 1.67TCr 1,50700Cr | Net Debt 2025 * | 1.5TCr 1.38TCr 1,25100Cr | EV / Sales 2025 * | 14.3 x |
| P/E ratio 2024 * |
61.4
x | P/E ratio 2025 * |
44.2
x | Employees | 43,000 |
| Yield 2024 * |
0.63% | Yield 2025 * |
0.73% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 week | +1.03% | ||
| 1 month | +2.08% | ||
| 3 months | +2.62% |
1 week
19.30
19.60
1 month
18.3020.40
Current year
18.3025.20
1 year
18.3025.20
3 years
18.3025.20
5 years
18.3025.20
10 years
18.3025.20
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01/01/01 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 19.6 | -.--% | 0 |
| 30/24/30 | 19.6 | +1.55% | 0 |
| 29/24/29 | 19.3 | -0.52% | 0 |
| 28/24/28 | 19.4 | -0.51% | 0 |
| 27/24/27 | 19.5 | +0.52% | 0 |
Delayed Quote Deutsche Boerse AG, May 31, 2024 at 06:59 pm IST
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.83% | 60TCr | |
| -6.30% | 35TCr | |
| +15.15% | 32TCr | |
| +4.05% | 28TCr | |
| +15.00% | 24TCr | |
| +9.78% | 21TCr | |
| -5.52% | 21TCr | |
| +6.17% | 16TCr | |
| -0.45% | 16TCr |
- Stock Market
- Equities
- LLY Stock
- LLY0 Stock
